“These data support pembrolizumab plus [chemoradiotherapy] as the new standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, and as an appropriate control arm in future clinical trials,” according to study author Linda Rosenbaum Duska, MD, MPH.
A statistically significant and/or clinically meaningful improvement in efficacy was noted when pembrolizumab (Keytruda) plus chemoradiotherapy followed by pembrolizumab was used to treat patients with newly diagnosed, previously untreated, high-risk, stage IB to IIB with node-positive disease or stage III to IVA disease regardless of nodal status in locally advanced cervical cancer, according to the second interim analysis findings from the phase 3 KEYNOTE-A18 trial (NCT04221945) presented at the 2025 Society of…